نوع مقاله : مقاله پژوهشی

نویسندگان

1 عضو هیات علمی /دانشگاه شهیدمدنی آذربایجان

2 استاد بیولوژی - دانشگاه تبریز

چکیده

چکیده:
سابقه و هدف : سرطان تیروئید شایع‌ترین بدخیمی سیستم اندوکرینی است. سرطان تیروئید در هر سن و جنس می‌تواند رخ دهد. از مهمترین ژن‌های سرکوبگر درگیر در سرطان، ژن TP53 می‌باشد. که در تنظیم و توقف چرخه سلولی و اپوتپوز نقش مهمی دارد. جهش‌هایی که سبب غیرفعال‌شدن ژن TP53 می‌شوند، در بیش از 50 درصد بدخیمی‌ها‌ی انسان دیده می‌شود. هدف از این تحقیق، تعیین جهش های ژن TP53 در مبتلایان سرطان تیروئید در جمعیت استان آذربایجان‌شرقی بود.
مواد و روش ها : در این مطالعه توصیفی، تعداد 40 نمونه توموری از بیماران آذری مبتلا به سرطان تیروئید که طی سالهای 86 تا 88 به بیمارستانهای شهر تبریز مراجعه کرده بودند ، جمع آوری شد و DNA آنها به روش پروتئینازK استخراج گردید. جهش های ژن TP53 در اگزون های پنج تا هشت بوسیله واکنش های زنجیره ای پلیمراز (PCR) و توالی یابی مستقیم مورد بررسی قرار گرفت.
یافته ها: نتایج حاصل وجود 5/12 درصد تغییرات ژنتیکی را در بیماران نشان می دهد که مربوط به جهش ها و پلی مورفیسم های تک نوکلئوتیدی می باشند. جهش درCodon216(GTG>GTA)، Codon215(AGT>ATT) و Codon273 (CGT>CAT) هرکدام در یکی از بیماران و دو پلی مورفیسم 14181C>T و14201T>G در اینترون هفت به طور پیوسته در دو نمونه دیگر شناسایی گردید.
بحث: این نتایج تا حدی وضعیت جهش های ژن TP53 را در بین مبتلایان تیروئید آذری روشن ساخته و مسیر را برای مطالعات بعدی فراهم می سازد.

کلیدواژه‌ها

موضوعات

عنوان مقاله [English]

Detection of mutations within exons 5 to 8 of the TP53 gene among Azeri patients with sporadic thyroid carcinoma

نویسندگان [English]

  • nasser pouladi 1
  • mohammadali hosseinpourfeizi 2

1 assistant professor azarbaijan shahid madani university

2 professor-biology

چکیده [English]

Background: Thyroid cancer is the most common malignant endocrine tumor, and the incidence was rising worldwide over the last three decades. TP53 is one of the most important tumor suppressor genes in the genome, and its mutations are found in approximately 50% of human cancers. It plays pivotal roles in the regulation of cell cycle arrest and apoptosis. The aim of this study was to analyze TP53 gene mutations among thyroid cancer patients in East- Azerbaijan.
Material and Methods: 40 tumor samples have been collected from thyroid cancer patients from Tabriz hospitals between 2007-2009. DNA was extracted by Proteinase K – Iso propanol method and then the mutations in p53 gene from exon5 to exon8, were detected by Polymarase Chain Reactions (PCR) and direct sequencing techniques.
Results: Alterations in the p53 gene were detected in 12.5% of the patients, including single nucleotide polymorphisms and mutations, including codon216 (GTG>GTA), codon215 (AGT>ATT) and codon273 (CGT>CAT) mutations (each mutation in one of the cases) and two linked polymorphisms 14181C>T and 14201T>G (in two cases).
Conclusion: This result helps us to clarify p53 mutation status among Azerbaijani thyroid cancer patients.

کلیدواژه‌ها [English]

  • p53 gene
  • Thyroid
  • cancer
  • Mutation
 
 
[1].   Raymon H, Grogan E, Mitmaker J, Orlo H, Clark. The evolution of biomarkers in thyroid cancer form mass screening to a personalized Biosig nature. Cancers. 2010; 2: 885-912. doi: 10, 3390/ cancers 2020885.
[2].   Wartofsky L. Increasing world incidence of thyroid cancer: Increased detection or higher radiation exposure? Hormones. 2010; 9(2): 103-108.
[3].   Larijani B, Aghakhani S, Haghpanah V. Review of thyroid cancer in Iran. Austral - Asian Journal of Cancer. 2005; 4(4): 199-203.
[4].   Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clinical Oncology. 2010; 22: 395-404.
[5].   Kilfoy BA, Zheng T, Holford TR et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control. 2009; 20: 525-531.
[6].   Mohammad Khanlou Z, Pouladi N, Hosseinpour Feizi M, Pedram N. Lack of associations of the MDM4 rs4245739 polymorphism with risk of thyroid cancer among Iranian-Azeri patients: a case-control study. Asian Pac J Cancer Prev. 2017; 18(4): 1133-1138.
[7].   Varley JM. Germline TP53 mulations and li- fraumeni syndrom Human. Mutation. 2003; 21: 313-320.
[8].   Stegh AH. Targeting the p53 signaling pathway in cancer therapy- The promises, challenges, and perils. Expert Opin Ther Targets. 2012; 16(1): 67-83.
[9].   Lorne J, Hofseth S, Hussain P, Curtis C. Ha. p53: 25 years after its discovery. TRENDS in Pharmacological. Sciences. 2004; 25(4): 177-181.
[10].Ferraiuolo M, Verduci L, Blandino G, Strano S. Mutant p53 protein and the hippo transducers YAP and TAZ: a critical oncogenic node in human cancers. Int J Mol Sci. 2017; 18(5): 1-29.
[11].Antico Arciuch VG, Russo MA, Dima M, Kang KS, Dasrath F, Liao XH, Refetoff S, Montagna C, Di Cristofano A. Thyrocyte-specific inactivation of P53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget. 2011; 2(12): 1109-26.
[12].Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. Gene P53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. The Journal of Clinical Investigation. 1993; 91(4): 1753-60.
[13].Khani H, Hosseinpourefeizi M, Pouladi N, Chaparzadeh N, Montazeri V, Azarfam. Detection of P53 gene exons 5 and 6 mutations among East Azerbaijani women with breast cancer. ZUMS Journal. 2011; 20(78): 36-46.
[14].Pouladi N, Hosseinpourfeizi MA, Khani H. Evaluation of mutations in exons 7 and 8 of TP53 gene in breast cancer patients from Azarbaijan. J Babol Univ Med Sci. 2016; 18(2):19-25
[15].Dehghan R, Hosseinpour Feizi MA, Pouladi N, Babaei E, Montazeri V, Fakhrjoo A, Sedaei A, Azarfam P, Nemati M. Association of P53 (-16ins-Pro) haplotype with the decreased risk of differentiated thyroid carcinoma in Iranian-Azeri patients. Pathol Oncol Res. 2014 Nov 20.
[16].Hossein Pour Feizi M, Ravanbakhsh Gavgani R, Pourahmad R, Pouladi N, Azarfam P, Montazeri V. Association of p53 Arg/Pro polymorphism at codon 72 with risk of breast cancer in East Azerbaijani women. J Babol Univ Med Sci. 2012; 14(2): 31-8. [in Persian]
[17].http://www.umd.be:2072/4DACTION/OPMA4R/1. Available from Jun 2012.
[18].p53 knowledge base. Retrieved from http://p53.bii.a-star.edu.sg/aboutp53/snps/index.php.
[19].Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009; 4(7): 1073-81 Available at: http://sift.bii.a-star.edu.sg/www/SIFT_seq_submit2.html [Accessed 14 Oct. 2016].
[20].Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. Nat methods. 2010; 7(4): 248-249. Available at: http://genetics.bwh.harvard.edu/pph2/ [Accessed 14 Oct. 2016].
[21].Berggren P, Hemminki K, Steineck G. p53 intron 7 polymorphisms in urinary bladder cancer patients and controls. Stockholm Bladder Cancer Group. Mutagenesis. 2000; 15(1): 57-60.
[22].Shiraishi K, Kato S, Han SY, Liu W, Otsuka K, Sakayori M, Ishida T, Takeda M, Kanamaru R, Ohuchi N, Ishioka C. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem. 2004; 279(1): 348-55. Epub 2003 Oct 13.
[23].Kato SL, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003; 100(14): 8424-9. Epub 2003 Jun 25.
[24].Duntas L, Grab-Duntas BM. Risk and prognostic factors for differentiated thyroid cancer. Hell J Nucl Med. 2006; 9(3): 156-62.
[25].Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007; 28(6): 622-629.
[26].Tan BS, Tiong KH, Choo HL, Chung FF, Hii LW, Tan SH. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). Cell Death Dis. 2015; 6: e1826.
[27].Tan BS, Tiong KH, Choo HL et al. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). Cell Death Dis. Jul. 2015; 16(6): e1826.
[28].Sadeghi M, Motovali Bashi M, Hojati Z. Association of a polymorphism in 1562 promoter nucleotide of collagenase IV with the age and type of metastasis in breast cancer. J Babol Univ Med Sci. 2009; 6(10): 7-13. [in Persian]
[29].Sedaie Bonab A, Pouladi N, Hosseinpourfeizi MA, Ravanbakhsh Gavgani R, Dehghan R, Azarfam P, Montazeri V, Fakhrjou A. Single-strand conformational polymorphism analysis of a common single nucleotide variation in WRAP53 gene, rs2287499, and evaluating its association in relation to breast cancer risk and prognosis among Iranian-Azeri population. Med Oncol. 2014; 31(9): 168
[30].Pouladi N, Kouhsari SM, Feizi MH, Dehghan R, Azarfam P, Farajzadeh D. Lack of association of intron 3 16 bp polymorphism of TP53 with breast cancer among Iranian-Azeri patients. Asian Pac J Cancer Prev. 2014; 15(6) :2631-4.
[31].Dulcie LAI, Visser-Grieve S, Xiaolong YANG. Tumour suppressor genes in chemotherapeutic drug response. Biosci. Rep. 2012; 32: 361-374.
[32].Sax JK, El-Deiry WS. P53 downstream targets and chemosensitivity. Cell Death Differ. 2003; 10:  413-417.
[33].Morgan SE, Kim R, Wang PC et al. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells. Oncogene. 2000; 19(43): 5010-9.
[34].Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 1999; 104: 263-269.....